Woman in Japan Dies 90 Minutes After Getting Pfizer mRNA COVID Shot
A 42-year-old woman in Aisai City (Aichi Prefecture), Japan died on Nov. 5, 2022, about 90 minutes after receiving a fourth dose of a COVID-19 biologic. The dose was from Pfizer/BioNTech’s experimental Comirnaty bivalent mRNA COVID shot tailored for the BA.5 subvariant of the Omicron virus.1 2 3
Ayano Iioka, received the shot at a mass vaccination site in the Aisai and began having an anaphylactic reaction and collapsed suddenly within five minutes of the vaccination. She developed difficulty breathing and complained of feeling like she was “suffocating.”1 2 3
A doctor administered oxygen to Iioka and attempted to give her a shot of epinephrine (adrenaline)—a drug that relaxes the muscles in the airways and tightens the blood vessels—but gave up after being unable to locate a vein for the injection.1 2 3 4
Iioka became nauseous and began vomiting a “blood-like foam.” All anaphylactic treatment was halted
when the doctor discovered blood in the woman’s vomit, leading the doctor to suspect there may be “abnormalities” in her lungs. The doctor was reported to have said, “I thought it was bleeding from the lungs because there was blood.”1 2 3Iioka was subsequently transported by ambulance to a local hospital where she died less than two hours later.1 2 3
The Aichi Medical Association said it will investigate the case, specifically the medical staff’s response, as the death was reported to it as a case of medical malpractice.1 According to an article in The Japan Times:
The group suspects her death may have been a result of an anaphylactic reaction to the vaccine, with her family alleging that medical staff failed to provide proper treatment despite her showing symptoms of an allergic response.1
Iioka was reported to have pre-existing conditions, so a spokesperson for the Aisai government said it is unclear if the woman’s death was due to the vaccination.1
Moderna and Pfizer Bivalent COVID Shots Approved in Japan
The Ministry of Health, Labor and Welfare of Japan earlier this month granted fast-track approval of Moderna’s experimental bivalent formulation of its Spikevax mRNA COVID shot for the BA.5 Omicron subvariant. In October, the Ministry granted fast-track approval the Comirnaty bivalent mRNA COVID shot for the BA.5.5 6
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References:
No comments:
Post a Comment